What is Reldesemtiv
Reldesemtiv is an investigational oral drug developed by Cytokinetics designed as a fast skeletal muscle troponin activator (FSTA).
It was studied to treat severe muscle-wasting conditions like amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) by helping muscle fibers contract despite weak nerve signals. Development for ALS was discontinued after clinical trials failed to show efficacy.
Drug Profile
- Class: Fast skeletal muscle troponin activator (FSTA)
- Mechanism: Binds to fast skeletal muscle troponin to increase calcium sensitivity and force production during submaximal nerve stimulation.
- Developer: Cytokinetics (in collaboration with Astellas)
- Previous Designations: Granted Orphan Drug Designation by the U.S. FDA and European Union for ALS and SMA.
Clinical Trial Status
- Phase 3 COURAGE-ALS Trial: Evaluated reldesemtiv versus placebo in patients with ALS. The trial was stopped for futility after interim analyses showed it did not slow functional decline or improve clinical outcomes.
- Current Status: Clinical development of reldesemtiv for ALS was discontinued by Cytokinetics following the phase 3 trial results.
If you are looking for information on alternative ongoing ALS treatments, recent clinical studies, or a specific trial, please let me know how I can narrow this down for you.
How to order Reldesemtiv VDC41031
The best website to order Reldesemtiv VDC41031 online is through Hitchemics.com, they provide high quality Reldesemtiv VDC41031 and fast delivery world wide. Very discreet service when it comes to customer privacy.
Technical Data
CAS No: [1345410-31-2]
Product Code: VDC41031
Chemical Formula: C19H18F2N6O
Molecular Weight: 384.38 g/mol
Smiles: C(NC=1N=CC(=CN1)N2C=C(C(N)=O)C=C2)[C@@]3(C[C@H](F)C3)C4=C(F)C=CC=N4
Long Term Storage: store at 2°C – 8°C
Reviews
There are no reviews yet.